scispace - formally typeset
C

Christopher J. Krco

Researcher at Mayo Clinic

Publications -  85
Citations -  3505

Christopher J. Krco is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Antigen & Major histocompatibility complex. The author has an hindex of 32, co-authored 85 publications receiving 3272 citations. Previous affiliations of Christopher J. Krco include University of Rochester.

Papers
More filters
Journal ArticleDOI

PD-1 Restrains Radiotherapy-Induced Abscopal Effect

TL;DR: SABR induces an abscopal tumor-specific immune response in both the irradiated and nonirradiated tumors, which is potentiated by PD-1 blockade, and has the potential to translate into a potent immunotherapy strategy in the management of patients with metastatic cancer.
Journal ArticleDOI

Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma

TL;DR: The observations suggest that sB7-H1 may be detected in the sera of ccRCC patients and that s B7- H1 may systemically impair host immunity, thereby fostering cancer progression and subsequent poor clinical outcome.
Journal ArticleDOI

Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma

TL;DR: In contrast, CD4+CD25+Foxp3− T cells, which may represent a unique set of Tregs or activated helper T cell, was significantly associated with outcome, which is in contrast to previous studies which have suggested that elimination of T Regs may augment natural and pharmacologic immunity.
Journal ArticleDOI

Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes.

TL;DR: Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.
Journal ArticleDOI

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

TL;DR: B7-H1 is expressed in a substantial proportion of malignant pleural mesotheliomas and is associated with poor survival and may have important therapeutic implications for the management of mal cancers.